Drugs / beta-glucan
beta-glucan
also known as
TR 987 · Beta-1,3/1,6-D-Glucan · GLYC-101 · β-1,3/1,6-D-glucan · CP105F · Glucoprime · Glucoprime gel · Imuneks · +3 more
Trials 14 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01829373 | Oct 2011 → Jun 2012 | lung cancer | Edward Hirschowitz | Completed | No outcome recorded |
| Phase 1 | NCT00492167 | Sep 2005 → Mar 2022 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00087009 | May 2004 → Aug 2008 | leukemia, lymphoma, lymphoproliferative syndrome | Memorial Sloan Kettering Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT00037011 | Nov 2001 → Jan 2005 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00656474 | Mar → Apr 2008 | — | TR Therapeutics | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05079529 | Jun → Dec 2021 | cardiovascular-kidney-metabolic syndrome | University of Brawijaya | Unknown | No outcome recorded |
| Phase 2 | NCT00792688 | Oct 2008 → Jan 2010 | — | TR Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00089258 | Jul 2004 → Nov 2006 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT04162314 | Jan 2020 → Sep 2021 | uveitis | Faculty of Medicine, University of Indonesia | Unknown | No outcome recorded |
| Phase 2/3 | NCT04029649 | Aug 2019 → Dec 2020 | ulcerative colitis | Faculty of Medicine, University of Indonesia | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06707103 | Apr 2025 → Dec 2026 expected | ulcer of lower limbs, venous insufficiency | TR Therapeutics | Recruiting | No outcome recorded |
| Phase 3 | NCT06707090 | Jan 2025 → Dec 2027 expected | ulcer of lower limbs, venous insufficiency | TR Therapeutics | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02807220 | Feb → Apr 2017 | common cold | Imuneks Farma ilac San. Tic. A.S. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07299942 | Jul 2024 → Jan 2025 overdue | — | University of Glasgow | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT03857256 Comparator | May 2019 → Aug 2021 | hyperlipidemia | Montreal Heart Institute | Completed | No outcome recorded |
| Phase 2 | NCT03154619 Comparator | Nov 2016 → Apr 2019 overdue | ulcer of lower limbs | SerenaGroup, Inc. | Active not recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02402296 Comparator | Jan 2013 → Jun 2014 | periodontitis, aggressive | Al-Azhar University | Completed | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | beta glucan | “We conducted a phase I study (clinicaltrials.gov NCT00492167) to determine the safety of the combination of yeast-derived beta glucan (BG) and anti-GD2 murine monoclonal...” PMID 34944886 ↗ Dec 20216“an oral medication called beta glucan, an over the counter oral dietary supplement” NCT01829373 ↗ |
| Known as | Beta-1,3/1,6-D-Glucan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04162314 ↗ |
| Known as | CP105F | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03857256 ↗ |
| Known as | Glucoprime | “topically applied Glucoprime gel (GLYC-101 gel 1.0 %)” NCT00656474 ↗ |
| Known as | Glucoprime gel | “topically applied Glucoprime gel (GLYC-101, 0.1% and GLYC-101, 1.0%)” NCT00792688 ↗ |
| Known as | GLYC-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00792688 ↗ |
| Known as | Imuneks | “Study Drug: Imuneks 10 mg Capsules, containing 10 mg micronized Beta-1,3/1,6-D-glucan derived from baker's yeast of which at least 80 % is below 10 microns” NCT02807220 ↗ |
| Known as | micronized Beta-1,3/1,6-D-glucan | “Study Drug: Imuneks 10 mg Capsules, containing 10 mg micronized Beta-1,3/1,6-D-glucan derived from baker's yeast of which at least 80 % is below 10 microns” NCT02807220 ↗ |
| Known as | Oat beta-glucan | “CP105F (Oat beta-glucan) 1.5g (1 tablet of 0.5g TID) for 12 weeks.” NCT03857256 ↗ |
| Known as | Polysaccharide Peptide | “Hypothesis of this study is β-1,3/1,6-D-Glucan (Polysaccharide Peptide) from mycelia extract of Indonesia's Ganoderma lucidum can acts as a chronic anti-inflammatory and...” NCT05079529 ↗ |
| Known as | TR 987 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03154619 ↗ |
| Known as | β-1,3/1,6-D-glucan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02402296 ↗ |
| Action | Activate | “prime leukocyte dectin-1 and CR3-receptors and enhance anti-tumor cytotoxicity” PMID 34944886 ↗ Dec 2021 |
| Modality | Other / unclassified | “Beta glucans, complex polysaccharides” PMID 34944886 ↗ Dec 2021 |
| Route | Oral | “Patients receive oral beta-glucan” NCT00037011 ↗ |